Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.19
Views: 520
Rating:

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA

Dr Neeraj Agarwal comments on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the ENZAMET trial.

This was a phase III internationally randomised trial in which patients with mHSPC who received testosterone suppression were also given enzalutamide.
 

Watch Dr Sweeney's press conference here, and interview here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation